Please use this identifier to cite or link to this item:
http://dspace.bits-pilani.ac.in:8080/jspui/xmlui/handle/123456789/13482Full metadata record
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | Gaikwad, Anil Bhanudas | - |
| dc.date.accessioned | 2023-12-21T06:43:27Z | - |
| dc.date.available | 2023-12-21T06:43:27Z | - |
| dc.date.issued | 2019-10 | - |
| dc.identifier.uri | https://www.sciencedirect.com/science/article/abs/pii/S1734114019301185 | - |
| dc.identifier.uri | http://dspace.bits-pilani.ac.in:8080/xmlui/handle/123456789/13482 | - |
| dc.description.abstract | Neprilysin inhibitors (NEPi) are assisting the renin-angiotensin system (RAS) inhibitors in halting diabetic cardiomyopathy (DCM). Away from conventional tactic, a recent report revealed the renoprotective potential of NEPi and angiotensin-converting enzyme (ACE2) activator combination therapy against diabetic nephropathy. However, this combination so far not evaluated against DCM, thus the present investigation aiming the same. | en_US |
| dc.language.iso | en | en_US |
| dc.publisher | Elsevier | en_US |
| dc.subject | Pharmacy | en_US |
| dc.subject | Cardiomyopathy | en_US |
| dc.subject | Neprilysin inhibitors (NEPi) | en_US |
| dc.subject | Angiotensin-converting enzyme (ACE2) | en_US |
| dc.title | Simultaneous inhibition of neprilysin and activation of ACE2 prevented diabetic cardiomyopathy | en_US |
| dc.type | Article | en_US |
| Appears in Collections: | Department of Pharmacy | |
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.